Biohaven announces positive data from its exploratory electroencephalogram (eeg) biomarker study of bhv-7000, completion of once-daily formulation development, and plan to initiate phase 3 pivotal studies

Examination of eeg in healthy subjects administered single doses of bhv-7000 confirmed central nervous system (cns) activity consistent with effects observed with other antiseizure medications. eeg results demonstrated dose-dependent and time-dependent effects of bhv-7000 on cns target engagement in study subjects: at the lowest dose studied of 10 mg, subjects with targeted drug concentrations ≥ ec50 showed a mean increase in eeg spectral power in beta and gamma bands while there were no meaningful changes in spectral power in subjects with drug concentrations
BHVN Ratings Summary
BHVN Quant Ranking